Sarepta Therapeutics
SRPT
SRPT
254 hedge funds and large institutions have $3.03B invested in Sarepta Therapeutics in 2017 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 78 increasing their positions, 91 reducing their positions, and 31 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
254
Holders Change
+21
Holders Change %
+9.01%
% of All Funds
5.77%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
56
Increased
78
Reduced
91
Closed
31
Calls
$325M
Puts
$287M
Net Calls
+$38M
Net Calls Change
-$18.1M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$193M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$60.5M |
| 3 |
Morgan Stanley
New York
|
+$31.5M |
| 4 |
PP
PDT Partners
New York
|
+$31.5M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$26.6M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$88.2M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$61.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$59.3M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
-$33.6M |
| 5 |
State Street
Boston,
Massachusetts
|
-$30.6M |
